Literature DB >> 14700510

Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.

Joel M Neutel1, David H G Smith, Michael A Weber.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs) increase arterial compliance and decrease left ventricular mass in hypertensive patients. This study examined whether combined therapy has greater arterial and cardiac effects than doubled doses of the individual drugs.
METHODS: This prospective, randomized, open-label study enrolled 106 patients aged >/=18 years with mild-to-moderate hypertension. Patients were randomized to 5 mg of amlodipine or 20 mg of benazepril for 2 weeks; then, depending on randomization assignment, they were force-titrated to 10 mg of amlodipine or 40 mg of benazepril monotherapy, or to combination amlodipine (5 mg) and benazepril (20 mg) treatment for 22 weeks. Arterial distensibility was assessed using the DynaPulse ambulatory system, and left ventricular mass was assessed by echocardiography.
RESULTS: Combination therapy (0.71% +/- 0.51% mL/mm Hg) increased arterial distensibility more than amlodipine (0.28% +/- 0.69% mL/mm Hg; P =.008) or benazepril (0.39% +/- 0.62% mL/mm Hg; P =.03) monotherapies. Left ventricular mass decreased more with combination treatment (65 +/- 56 g) than with amlodipine (28 +/- 4 g; P <.02); the difference from benazepril (42 +/- 50 g) was not significant.
CONCLUSIONS: Combined ACE inhibitor and CCB treatment was more efficacious than high doses of the individual agents in increasing arterial compliance and reducing left ventricular mass. These findings indicate that appropriately selected combinations of antihypertensive drugs might have enhanced cardioprotective effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14700510     DOI: 10.1016/j.amjhyper.2003.08.002

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  21 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

Review 2.  Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Authors:  Nicolás Renna; Daniel Piskorz; Diego Stisman; Diego Martinez; Ludmila Lescano; Sergio Vissani; Walter Espeche; Diego Marquez; Roberto Parodi; Diego Naninni; Marcos Baroni; Daniel Llanos; Rocio Martinez; Jessica Barochinner; Gustavo Staffieri; Fernando Lanas; Mónica Velásquez; Marcos Marin; Bryan Williams; Irene Ennis
Journal:  J Hum Hypertens       Date:  2021-06-04       Impact factor: 3.012

3.  Optimizing blood pressure control in patients with chronic kidney disease.

Authors:  Biff F Palmer; Andrew Z Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

Review 4.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

5.  Relationship between elevated arterial stiffness and increased left ventricular mass in adolescents and young adults.

Authors:  Elaine M Urbina; Lawrence M Dolan; Connie E McCoy; Philip R Khoury; Stephen R Daniels; Thomas R Kimball
Journal:  J Pediatr       Date:  2011-05       Impact factor: 4.406

Review 6.  [Isolated systolic hypertension. An independent disease].

Authors:  J Scholze
Journal:  Herz       Date:  2010-10-16       Impact factor: 1.443

Review 7.  Combination drug treatment of hypertension: have we come full circle?

Authors:  Addison A Taylor
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 8.  Combination therapy as first-line treatment for hypertension.

Authors:  Irene Gavras; Talma Rosenthal
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

9.  Complete reversal of hypertensive cardiomyopathy after initiating combined antihypertensive therapy.

Authors:  Marijn J Holl; Sweder W van de Poll; Michelle Michels
Journal:  BMJ Case Rep       Date:  2016-04-08

10.  Irbesartan improves arterial compliance more than lisinopril.

Authors:  Khalid Ali; Chakravarthi Rajkumar; Francesco Fantin; Rebekah Schiff; Christopher J Bulpitt
Journal:  Vasc Health Risk Manag       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.